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Identification of novel light-activated chemical tools  
for the study of TRPA1-mediated non-visual photosensation 
Darya Cinyee Cheng 
 
ABSTRACT 
Over the past decade, the transient receptor potential ankyrin 1 (TRPA1) receptor has been 
extensively studied because of its wide distribution across the human body and its roles in many 
aspects of sensation, some of which are physiological and others of which are 
pathophysiological. A member of the TRP channel family, TRPA1 is most commonly found in 
somatosensory neurons present in nociceptors, especially the dorsal root ganglia and trigeminal 
ganglia, but its expression has been reported in tissues as disparate as the cells of the inner 
ear, non-neuronal cells in the small and large intestines and lungs, and in the beta islet cells of 
the pancreas. Physiologically, TRPA1’s primary role is as a nociceptive chemosensor detecting 
exogenous agonists that are irritants, such as AITC from wasabi, and endogenous agonists that 
are indicators of oxidative stress, such as H2O2. However, when TRPA1 becomes dysregulated, 
its physiological roles can become distorted. Research has demonstrated that TRPA1 is 
involved in many pathologies including chronic pain and inflammation, neuropathic pain, itch, 
and respiratory diseases, but to date, few TRPA1-targeting therapeutics have been successful, 
and it is evident that greater understanding of the receptor is required to address this need. 
Recently, the discovery of optovin revealed that a synthetic photoreactive compound could 
confer photosensitivity onto vertebrate TRPA1, but much is still unknown about photo-
dependent TRPA1 activation. One way to approach this question is through identification of 
additional chemotypes that act similarly to optovin. In this dissertation, I describe the process of 
identifying such compounds and the characterization of their properties. Analysis of data from a 
large-scale, behavior-based chemical screen conducted in larval zebrafish established a small 
  vii 
subset of compounds that induced a strong behavioral response to light. Structural analysis 
showed that the hit compounds were in fact structurally diverse, and photochemical, behavioral, 
and toxicity studies uncovered characteristics unique to each compound. Experiments using 
TRPA1 mutant zebrafish confirmed that a subset of these hits are TRPA1-dependent. Together, 
these structurally, photochemically, and pharmacologically diverse compounds form a tool set 
that can be used to modulate the TRPA1 receptor, allowing future researchers to gain a better 
understanding of the receptor’s characteristics and mechanisms, research its roles in sensation 
and photo-behaviors, and identify therapeutics to address pathologies caused by its 
dysregulation. 
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Chapter 1: The TRPA1 receptor as a research and therapeutic target 
The transient receptor potential ankyrin 1, or TRPA1, receptor is one of 28 members of the 
transient receptor potential (TRP) channel family. Structurally, it comprises four identical 
subunits, each of which contains six transmembrane alpha helices. These subunits surround a 
central pore and selectivity filter, which is formed from the fifth and sixth helices of each 
subunit1. The intracellular N-terminal domain contains the “allosteric nexus”, which contains the 
binding site for many agonists2, along with 14-18 ankyrin repeats depending on the species1 
(Fig. 1.1). TRPA1 is found most commonly in somatosensory neurons present in nociceptors, 
such as the dorsal root ganglia and trigeminal ganglia, but has also been reported in cell types 
as varied as the hair cells of the inner ear, non-neuronal epithelial cells in the small and large 
intestine, non-neuronal lung cells (including fibroblasts and smooth muscle cells), and in the 
insulin-producing beta islet cells of the pancreas. Once an agonist binds, TRPA1 becomes 
permeable to cations such as Na+ and Ca2+, which depolarize the membrane and initiate Ca2+ 
signaling in the cell.1 (Fig. 1.2).  
 
Physiological roles of the TRPA1 receptor 
TRPA1 shares loose identity with the TRPV1 channel, which is responsible for the “hot” 
sensation caused by capsaicin in hot peppers3. Similarly, TRPA1 is responsible for the burning, 
“sinus-clearing” sensation that is induced when consuming foods such as wasabi or cinnamon, 
which contain allyl isothiocyanate (AITC)4 and cinnamaldehyde (CA)1, respectively. These 
exogenous electrophilic agonists, along with other compounds such as acrolein (from diesel 
exhaust) and allicin (from garlic extract), form covalent adducts with reactive cysteine and lysine 
residues in the allosteric nexus (Fig. 1.1). Together, these observations suggest that one of 
TRPA1’s major roles is as a nociceptive chemosensor that induces pain when activated (Fig. 
1.2), thereby serving as a warning to limit further exposure to the reactive irritant1.  
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Figure 1.1 TRPA1 channel structure 
TRPA1 is homotetramer, comprising four identical subunits, one of which is depicted here. Each 
subunit contains six transmembrane alpha helices (labeled S1-S6). In the N-terminal domain, 
the allosteric nexus (with reactive cysteine and lysine residues) can be found, along with the 14-
18 ankyrin repeats that give TRPA1 its name. Together, the four subunits surround a central 
pore with a selectivity filter formed from the region between helices S5 and S6. (Adapted from 
Chen and Hackos 20151). 
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Figure 1.2 TRPA1 is found on nocicpetive somatosensory neurons 
Following TRPA1 activation by either exogenous agonists (such as AITC, cinnamaldehyde, 
acrolein, and allicin) or endogenous agonists (such as H2O2), TRPA1 becomes permeable to 
cations such as Na+ and Ca2+, which depolarize the membrane and initiate Ca2+ and 
neurotransmitter signaling. Because TRPA1 channels are most commonly expressed in the 
somatosensory neurons of nociceptors, activation of TRPA1 can result in the sensation of pain. 
(Adapted from Andersson et al. 20115). 
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Additionally, TRPA1 can also be activated endogenously. Agonists include oxidized lipids, 
nitrated lipids, and reactive oxygen species (ROS) such as H2O26, all of which may act as 
indicators of oxidative stress1. Likewise, TRPA1 can be activated as part of the downstream 
pathway of G-protein coupled receptors. One such pathway is through the phospholipase-C 
coupled receptors that detect pruritic and pro-inflammatory agents, thus forming a direct link 
between TRPA1 and the sensation of itch2. Finally, TRPA1 has also been implicated in other 
modes of nociception, including mechanosensitivity7, heat sensitivity8, and cold sensitivity9.   
 
Pathophysiological roles of TRPA1 
Though TRPA1 plays an important role in nociception, its dysregulation has been implicated in 
several pathophysiologies, many of which are distorted versions of TRPA1’s normal functions. 
Most notably, TRPA1 has been shown to play a major role in pain and inflammation. A gain-of-
function mutation in TRPA1 causes a genetic disorder known as familial episodic pain syndrome 
that is characterized by debilitating upper body pain10. Likewise, TRPA1 has been demonstrated 
to play a role in neuropathic pain, a form of pain which is due to nervous system damage or 
dysfunction rather than tissue injury11. Increased expression of TRPA1 receptors has been 
reported at sites of nerve injury12, and methylglyoxal, a reactive compound produced in large 
amounts in diabetes, activates TRPA113, while TRPA1 blockade reduces hypersensitivity arising 
from diabetic neuropathy14. Chemotherapy-induced peripheral neuropathy is likewise thought to 
be mediated through TRPA1, potentially through oxidative stress by-products produced 
following exposure to chemotherapy drugs11,15. Chronic inflammation has been linked to TRPA1 
as well. While acute inflammation is important and useful in signaling the immune system to 
repair damage and heal the body, chronic inflammation and pain is detrimental, and studies 
have shown that many of the proinflammatory agents released as part of the “inflammatory 
soup”, such as ROS and oxidized or nitrated lipids4, are TRPA1 activators11. 
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In addition to pain and inflammation, TRPA1 is also known to be involved in other pathologies. 
Beyond its role in physiological levels of pruritus, elevated expression levels have been 
observed in atopic dermatitis lesions in both humans and mice16, while TRPA1 antagonists were 
able to attenuate itch-scratching behaviors in mouse models of allergic contact dermatitis17. 
Chronic activation of TRPA1 has also been observed in respiratory diseases. Due to its function 
as a chemosensor, including as a sensor of airborne irritants, TRPA1 is highly expressed in the 
lungs and airways1. In conditions such as chronic cough, rhinitis, asthma, and chronic 
obstructive pulmonary disease (COPD), TRPA1 expression levels are elevated, and activation 
of receptors in these regions is greatly increased by elevated levels of both endogenous TRPA1 
ligands and pro-inflammatory mediators1. 
 
By virtue of its involvement in these and other pathophysiologies, many of which have few or no 
treatments, TRPA1 represents a promising therapeutic target. Novel chronic pain medications 
targeting TRPA1 may help relieve neuropathic pain, while alternatives to common pain relievers 
with unwanted side effects, like acetaminophen (hepatotoxicity)18 and ibuprofen (adverse 
gastrointestinal effects)19 - both of which are thought to act at least partially through TRPA11,20 - 
might be developed. Likewise, as evidence has shown that antagonists and blockade of the 
TRPA1 receptors can attenuate the effects of many conditions, including airway pathologies and 
itch, novel antagonists could also address the unmet need for therapeutics in these areas. 
 
Optovin: a reversible, light-activated TRPA1 agonist 
Recently, the discovery of optovin revealed that pharmacological activation of TRPA1 can be 
modulated by light. Using 3dpf (days post fertilization) larval zebrafish, which are blind and do 
not respond to light,  a large-scale behavior-based chemical screen of a 10,000 compound 
library was performed to search for hits that would allow for in vivo, optical control of 
endogenous channels21. This screen identified optovin (Fig. 1.3) as a compound that reliably 
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induced a strong period of motor activity following light exposure. Optovin-treated animals 
responded to stimulation by 387-nm (violet) light but not to other wavelengths, and multiple 
responses could be triggered with repeated pulses of light, showing that this novel, behavior-
modifying compound could induce rapid and reversible motor excitation in response to violet 
light stimuli21. To determine whether the purple-light response behavioral profile was unique to 
optovin, the profiles for optovin and 700 known, annotated neuroactive compounds (including, 
but not limited to, compounds targeting the adrenergic, serotonergic, and glutamatergic 
pathways) were hierarchically clustered. Clustering revealed that the behavioral profile induced 
by optovin was unique, and that optovin was in fact on its own branch of the dendrogram (Fig. 
1.3), suggesting that this compound is functionally distinct from known neuroactive 
compounds21. Further experiments identified TRPA1 as the receptor target for optovin. While 
wild type and heterozygous fish responded to violet stimuli, TRPA1 mutant fish did not. 
Transfection of HEK293T cells with human TRPA1 likewise demonstrated a response, as 
measured by calcium imaging, while green fluorescent protein (GFP) transfected cells did not21. 
Together, these results established that TRPA1 was both necessary and sufficient for the 
optovin response. As only a small subset of light-responsive TRPA1 receptors had been 
identified prior to optovin, this result represented a novel discovery that allowed for fine-tuned, 
spatiotemporal control of TRPA1 signaling via light in wild-type animals21. 
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Figure 1.3 Optovin is functionally distinct from other known neuroactive compounds 
A) The chemical structure of optovin21 
B) Hierarchical clustering of optovin with 700 other known neuroactive compounds revealed that 
the behavioral profile produced by optovin is unique. Additionally, this demonstrates that 
behavioral phenotypes can be used to identify new compounds and classify known compounds, 
and that behavioral profiling can identify compounds with different mechanisms of action21. 
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The need for novel light-dependent TRPA1 ligands 
Though the discovery of optovin represents an exciting new direction for TRPA1 research, much 
is still unknown about light-dependent TRPA1 activation. One way to approach this question is 
through identification of additional chemotypes that act similarly to optovin. Though structural 
analysis has suggested that optovin’s rhodanine ring may play an important role in its 
bioactivity, and several active structural analogues have been identified22, it is still unclear 
exactly how the light activation of optovin occurs. Therefore, it would be interesting to compare it 
to other structures that have a light-dependent effect. Furthermore, while optovin itself is already 
a useful research tool that allows for real-time, optical control of TRPA1 and the cells in which it 
is expressed, novel compounds may possess properties that render them more suitable for 
different experimental purposes. For example, compounds may vary in their selectivity or 
specificity, target specific populations of TRPA1 receptors in different locations or tissues, 
induce unique patterns of response with varying levels of control, and/or demonstrate diversity 
in other properties such as potency, sustained effects, and toxicity. Together, these proposed 
tools could reveal previously unknown characteristics of the receptor and its roles, as well as 
contributing more broadly to the understanding of TRPA1-dependent or other non-visual photo-
behaviors and light sensation in general in humans and other species. Finally, the discovery of 
more optovin-like compounds has the potential to lead to new therapeutics. As mentioned 
above, TRPA1 plays roles in pain, inflammation, and other pathophysiologies, so tools that 
target this receptor could be a starting point for new treatments. This goal is particularly 
important because current remedies for chronic pain, neuropathy, and other TRPA1-related 
conditions are often insufficient22. Such molecules could include new antagonists to block 
TRPA1’s effects, but they could also include those with new mechanisms, such as agonists of 
TRPA1 subpopulations, which might achieve an analgesic effect, as with acetaminophen5. In 
this dissertation, I report on efforts to identify new chemical probes of TRPA1 using large-scale 
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zebrafish behavioral assays. The results of these studies provide important new chemotypes of 
manipulating TRPA1 and light-dependent behavior. 
 
Large-scale screening to identify novel light-dependent TRPA1 ligands 
In order to identify novel light-dependent TRPA1 ligands, we performed a large-scale, behavior-
based novel chemical screen using larval zebrafish. While most high-throughput chemical 
screens are usually target based and performed in vitro, these methods have certain 
disadvantages; namely, they do not capture the full complexity of a vertebrate nervous system, 
and they make a priori assumptions about the targets of interest, thereby limiting their ability to 
detect compounds that achieve their effects through new pathways23. Given these limitations, 
we instead developed a system that screens compounds based on the behavioral phenotypes 
they induce in larval zebrafish in response to various stimuli. This method has a number of 
advantages over previous screening methods: first, by using zebrafish, we are able to capture 
behaviors from vertebrates with complex brains and nervous systems. As zebrafish and humans 
also share many conserved genes and neurotransmitter pathways, this provides results that are 
more relevant to humans than, for example, an isolated group of cells or Drosophila. Secondly, 
this method allows us to ascertain whether a compound has an effect in vivo during the early 
stages of screening before performing follow-up experiments. Finally, zebrafish larvae are small, 
relatively low cost, and they mature and reproduce quickly, making them suitable for high-
throughput testing in a 96-well plate format, unlike mice or rats23–25.  
 
To perform these experiments, zebrafish embryos are first collected at 7dpf. Following the 
sorting of healthy and unhealthy animals, eight larvae are pipetted, along with egg water, into 
each well of a 96-well plate. The larvae are then treated with the compounds of interest, along 
with both positive and negative controls. The entire plate is then placed into our automated 
behavioral phenotyping instrument. Designed in-house, this instrument consists of a large box 
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containing a camera, lighting, and multiple apparatus for creating stimuli, including LEDs with 
varying wavelengths of light, solenoids to create physical “tapping” stimuli, and speakers for 
audio stimuli (Fig. 1.4). Once the instrument is closed to block off outside stimuli, a custom 
script runs to control the activation of predetermined groups of stimuli (“assays”) arranged into a 
series (a “battery”) (Fig. 1.5). Beyond the standardized screening battery, assays and batteries 
can also be adjusted and customized to probe different aspects of a behavioral phenotype. As 
the battery is run, the camera records the responses of the treated larvae. The resulting video 
footage is then converted into a series of motion index (MI) values (Fig. 1.5), which represent 
the change in pixels from one frame to the next as a measure of movement, where a higher MI 
value signifies increased activity, and a lower MI signifies decreased activity. The entire series 
of MI values is then plotted as a line graph, or MI trace, over time, along with a graphical 
indicator of the corresponding stimuli (Fig. 1.5). By analyzing these MI values and traces, we 
can identify patterns of behaviors that act as a “barcode” for specific mechanisms of action24,25, 
and use that barcode to identify other compounds with similar phenotypes and mechanisms of 
action26. For example, one identified activity barcode is the “enhanced acoustic startle” 
response, characterized by a brief burst of activity in response to only one specific type of low-
volume acoustic stimulus. This behavioral pattern was shown to be a signifier for GABAAR 
ligands27. The optovin response, in contrast, is a sharp but more sustained increase in activity in 
response to a violet light stimulus (Fig. 1.5).  
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Figure 1.4 Automated behavioral phenotyping instrument 
A) Photograph of the instrument 
B) Schematic depicting instrument components. These include a camera, an infrared light 
source and visible-light blocking IR filter (to prevent confounding of the video images from 
stimuli light sources), an acrylic stage fitted with a groove to hold a 96-well plate, and diagnostic 
sensors. Stimuli apparatus include LEDs at various wavelengths, solenoids to produce a 
physical tap, and transducers to play audio28.  
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Figure 1.5 The optovin MI trace reveals that optovin induces a distinctive, violet light-
dependent response 
The motion index (MI, y-axis) is a measure of activity derived from the change in pixels from one 
frame of video to the next. The more pixels that have changed, the higher the MI, and the 
greater the activity. Here, the optovin (red) and DMSO (gray) MI values over time (x-axis) have 
been plotted together as MI traces for comparison. Along the bottom, a graphical depiction of 
stimuli at the time they occur allows for correlation to activity patterns. Blocks of color represent 
a light stimulus of the corresponding color. Vertical lines represent taps, with full lines 
representing a hard tap and the half lines representing a soft tap. The black rectangles are taps 
that occurred too closely together to be depicted separately. Optovin induces a distinct 
behavioral phenotype in which a sharp spike of activity occurs when the treated zebrafish larvae 
are exposed to violet light. Conversely, while there is a slight increase in activity in the DMSO-
treated larvae, the response is no more than 50% that of the optovin-treated fish, and it does not 
form peaks. 
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Focus of the dissertation 
The research described in this dissertation focuses on the discovery and characterization of 
novel, light-dependent, optovin-like compounds. The aim of this study is to identify these 
compounds and to furthermore confirm the optovin-like response as an indicator of light-
dependent TRPA1 ligands. Using this behavioral phenotyping methodology, we screened a 
chemical library containing over 30,000 novel compounds. Manual and computational analyses 
of the MI traces revealed potential hits, and confirmatory experiments identified a set of hit 
compounds that induced behaviors similar to that of optovin. Photochemical, behavioral, and 
toxicity studies characterized the compounds and illustrated similarities and differences, while 
experiments with mutant TRPA1 fish confirmed that a subset of the hit compounds were in fact 
TRPA1 dependent. Overall, the findings from the work described herein contribute new insights 
into the light-dependent activation of TRPA1 as well as a set of novel prototype compounds with 
varying characteristics that control TRPA1 with light. Together, this will enable future 
researchers to not only further explore the physiological roles of TRPA1, but to better 
understand its pathophysiological roles and to develop therapeutics to address the unmet need 
in those areas.  
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Chapter 2: Identification of compounds producing non-visual TRPA1-mediated 
photosensation in zebrafish 
 
ABSTRACT 
TRPA1 receptors are important sensors of chemical irritants. In most vertebrates, they do not 
normally respond to light. Previous studies have identified synthetic photoreactive compounds 
that confer photosensitivity onto vertebrate TRPA1. However, the pharmacology of TRPA1-
mediated non-visual photosensation remains poorly understood. To identify novel compounds 
that affect this process, we screened a large chemical library for compounds that increased 
light-elicited motor activity in larval zebrafish. This screen identified structurally diverse hit 
compounds. A subset of these compounds was photoreactive and produced specific behavioral 
phenotypes, and a subset of these additionally required functional TRPA1. Together, these 
studies improve our understanding of non-visual TRPA1-mediated photosensation. In addition, 
these studies provide novel prototype compounds for controlling TRPA1 with light.  
 
INTRODUCTION 
TRPA1 receptors are members of the transient receptor potential (TRP) channel family1. They 
are tetrameric ion channels2 with cytoplasmic ankyrin repeats that mediate sensitivity to thermal 
and chemical stimuli3. TRPA1 channels respond to a wide variety of reactive compounds 
including mustard oil4, industrial electrophiles5, drug metabolites6, and other compounds1,7. They 
mediate the inflammatory actions of environmental irritants and proalgesic agents8. In addition, 
they mediate cough9, inflammation5, and airway irritation10. A gain-of-function mutation in 
TRPA1 causes familial episodic pain syndrome11. These functions are important for diverse 
animal behaviors. 
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A relatively small subset of TRPA1 isoforms also respond to light. For example, in specific 
species of snakes, TRPA1 channels sense infrared light, aiding in prey capture12. In human 
melanocytes, TRPA1 channels respond to UV light, increasing protective pigmentation13. 
Furthermore, TRPA1 homologs are required for extraocular-light avoidance in planaria14. 
Additionally, TRPA1 channels mediate light-induced feeding deterrence15 and UV light 
avoidance16 in Drosophila. However, despite these examples, most TRPA1 isoforms, including 
human and zebrafish isoforms, do not normally respond to light3. 
 
Understanding TRPA1-mediated photosensation is important for understanding non-visual 
photo-behaviors. In humans, non-visual photo-behaviors include circadian rhythms, alertness17, 
and the pupil reflex18. In other species, more diverse non-visual behaviors are observed, 
including phototaxis in zebrafish19 and migration in birds20. In humans, all visual and non-visual 
behaviors are mediated by opsins21. In non-human species, non-visual behaviors are mediated 
by at least four additional types of photoreceptors including cryptochromes22, photoactivated 
adenylyl cyclases (PACs)23, gustatory related receptors (GRRs)24 and TRPA1. TRPA1-mediated 
non-visual photosensation may represent a potential ancestral function of this gene14.  
 
Previous studies have identified an exogenous small molecule that enables non-visual TRPA1-
mediated photosensation in vertebrates. This small molecule, optovin, is photoactivated by 
relatively short wavelengths of visible light25. Its activity is both light-dependent and rapidly 
reversible. It acts on various TRPA1 isoforms including human, mouse, and zebrafish25. As a 
result, it enables light-mediated control of transgenic cardiac cells26 and of endogenous TRPA1-
expressing neurons. Optovin’s photoactive properties have been linked to its rhodanine ring, a 
chemical moiety known to absorb light27. Several structural analogues of optovin have been 
identified that also produce similar phenotypes26. These data suggest that there may exist other 
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compounds that are functionally related to optovin that also produce non-visual photosensation 
via TRPA1.  
  
Despite this progress, few compounds beyond optovin have been identified that activate TRPA1 
in vivo via photoreactivity. To identify such compounds, we took a behavior-based drug profiling 
approach in zebrafish. Specifically, we screened a large chemical library for compounds that 
increased motor activity in response to light stimuli. This screen identified a set of structurally 
diverse hit compounds that were both photoreactive and produced specific behavioral profiles. A 
subset of these behavioral phenotypes required functional TRPA1. Together, these data 
improve our understanding of non-visual photosensation. In addition, they provide structurally 
diverse prototype compounds that may enable researchers to control endogenous TRPA1 with 
light.   
 
RESULTS 
 
Optovin produces a distinct behavioral profile  
Previous studies of how optovin affects behavior have primarily focused on early stage 
zebrafish embryos25. In embryos, the optovin response includes two spikes of motor activity – a 
large initial spike followed by a smaller subsequent spike of activity25. These motor activity 
spikes are thought to correspond to C-bend behaviors and swimming behaviors, respectively. 
However, less is known about optovin activity on zebrafish larvae, which exhibit more complex 
behaviors than embryos and are a powerful system for studying the vertebrate CNS. Therefore, 
it is important to characterize optovin activity in zebrafish larvae.  
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To determine how optovin affects zebrafish larvae, we treated larvae with various TRPA1 
ligands, tested them with different stimulus batteries, and analyzed their resulting behavioral 
profiles. First, larvae were treated with optovin for one hour, and, following a three-minute delay, 
exposed to a single pulse of light (10 min). Prior to light exposure, the optovin-treated animals 
demonstrated a significantly lower baseline activity level than DMSO-treated animals. Following 
activation of the stimulus, the response of optovin-treated animals could be divided into three 
phases. In the first phase, P1, onset of the stimulus elicited a sharp spike of motor activity, 
represented as the motion index, or MI (Fig. 2.1, 2.2). The MI during this spike increased 
approximately 8-fold over the optovin baseline (average MI during the pre-stimulus period), and 
P1 lasted for approximately 6s. (Fig. 2.1, 2.2, Table 2.1). In the second phase, P2, motor 
activity spiked again, increasing approximately 3-fold over the optovin baseline and lasting for 
approximately 1 minute (Fig. 2.1, 2.2, Table 2.1). In the third phase, P3, motor activity remained 
slightly higher than the optovin baseline for the duration of the stimulus (Fig. 2.1, 2.2). Following 
the stimulus, motor activity reverted to the optovin baseline (Fig. 2.1, 2.2). The P1 and P2 motor 
activity spikes were elicited only by blue (460nm) and violet (395nm) wavelengths, but not by 
longer wavelengths including green (523nm) and red (660nm) (Fig. 2.3, 2.4). Unlike in optovin-
treated animals, the P1 and P2 spikes were not observed in control larvae treated with the 
solvent alone. In P1, the control response only increased 2-fold from the solvent baseline – 
substantially less than the 8-fold increase observed in optovin-treated animals (Fig. 2.1, 2.2). In 
P2, the control response did not include a broad activity spike, unlike the optovin response. In 
P3, the control response did not decline (Fig. 2.1, 2.2). Another difference was that the control 
response included a distinct lights-off response at the end of P3 that was not observed in 
optovin-treated animals (Fig. 2.1).  
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Figure 2.1 Optovin induces a reproducible pattern of behavior 
Optovin treated zebrafish exposed to violet light (395nm) display three phases of activity that 
are distinct from control-treated larvae, shown here in a motor activity plot. Activity is shown as 
the motion index (MI) on the y-axis, with time on the x-axis. The optovin baseline is indicated by 
a solid horizontal black line. Phase are delineated by a broken vertical line. Colored bars below 
the motor activity plot indicate stimuli turning on (colored bar) and off (white bar); colors 
correspond to stimulus wavelength. 
 
 
 
 
 
Figure 2.2 The optovin-induced behavior profile is significantly different from the DMSO-
induced profile 
Bar plot showing average MI values (y-axis) for each optovin phase (x-axis). n = 72 optovin-
treated wells (red) and 40 DMSO-treated wells (gray); 8 fish/well. Error bars represent SEM. *p 
< 0.05. 
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Table 2.1 Optovin phase data 
Details of the optovin phases P1 and P2. P3 not included because it continues through the end 
of the stimulus (measured up to 10 minutes) and has no peak. n = 72 wells; 8 fish/well. 
 
 
 
Duration (s) Peak (MI) Peak time from stimulus start (s)
Peak time from 
phase start (s)
P1 6.32 ±0.31 40232.49 ±2011.91 1 ±0.06 1 ±0.06
P2 59.93 ±1.42 18113.38 ±2145.06 15.15 ±2.406 8.83 ±2.476
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Figure 2.3 Optovin induces the greatest increase in activity in response to blue and violet 
wavelengths 
Bar plot showing AUC (y-axis) of P1 and P2 spikes in optovin- (black) and DMSO- (gray) treated 
larvae following a 1 minute light stimulus. In optovin treated fish, P1 and P2 motor activity spikes 
following were elicited only by blue (460nm) and violet (395nm) wavelengths. Red (660nm), 
green (523nm), and no stimulus conditions did not elicit motor activity. n = 6 wells per stimulus 
for both optovin and DMSO; 8 fish/well. Error bars represent SEM. *p < 0.05. 
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Figure 2.4 Optovin light response to blue, red, and green wavelength stimuli  
Motion index traces for 6.25μM optovin-treated larvae exposed to 10 minutes of either violet 
(395nm), blue (460nm), red (660nm), or green (523nm) light. n = 6 wells per stimulus for both 
optovin and DMSO; 8 fish/well. 
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To determine how this optovin response compared to canonical TRPA1 ligands, larvae were 
treated with allyl isothiocyanate (AITC) and cinnamaldehyde (CA). In optovin-treated animals, 
multiple stimuli elicited multiple P1 and P2 spikes. By contrast, in neither AITC- nor CA- treated 
animals did multiple stimuli elicit P1 or P2 spikes (Fig. 2.5, 2.6). In both AITC- and CA- treated 
animals, motor activity increased throughout the assay, including during the P2 phase (Fig. 2.5). 
However, these increases in activity did not resemble the more distinct spikes observed in 
optovin-treated animals (Fig. 2.6). Notably, activity was also increased during the inter-stimulus 
intervals, whereas in optovin-treated animals activity is greatly decreased between stimuli (Fig. 
2.5, 2.6). In solvent-treated negative controls, multiple stimuli failed to elicit P1 and P2 spikes 
(Fig. 2.6). 
 
These data suggest that these P1 and P2 motor activity spikes may represent features of a 
specific behavioral profile that correlates with TRPA1-mediated non-visual photosensation, 
since these activity spikes specifically occurred in optovin-treated zebrafish larvae but were not 
observed in untreated larvae, nor in larvae treated with other TRPA1 ligands, such as AITC and 
CA. Alternatively, this behavioral profile may be a random coincidence with little predictive 
power for identifying novel TRPA1 ligands. To distinguish between these alternatives, we 
analyzed a larger number of compounds. 
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Figure 2.5 The optovin-induced behavioral profile differs from the behavioral profiles 
induced by known TRPA1 ligands 
Bar plot showing activity fold change vs. DMSO (y-axis) of optovin- (blue), allyl isothiocyanate- 
(AITC, orange), and cinnamaldehyde- (CA, gray) treated larvae during each of the optovin-
defined phases (x-axis). n = 8 wells per treatment; 8 fish/well. Error bars represent SEM.*p < 
0.05. 
 
 
 
 
 
Figure 2.6 MI traces illustrate difference between optovin-, AITC-, and CA-induced 
behavior 
Representative activity traces for larvae treated with the indicated compounds (red) or control 
(grey). AITC, allyl isothiocyanate; CA, cinnamaldehyde. n = 3 wells per treatment; 8 fish/well. 
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Large-scale chemical screening 
In previous studies, large-scale behavior based chemical screens in zebrafish have successfully 
identified diverse classes of neuroactive compounds related to anesthesia28, sleep29, fear30, 
feeding31, and antipsychotics32. Despite this progress, it remains unclear if novel compounds 
that produce TRPA1-mediated non-visual photo sensation can be identified based on their 
behavioral profiles. To answer this question, we analyzed behavioral data collected from a 
large-scale chemical screen (Fig. 2.7).  
 
In this screen, the chemical library included 30,656 structurally diverse compounds. These 
compounds were profiled on zebrafish larvae using a battery of behavioral phenotyping assays 
that included a variety of stimuli, including light-based stimuli. The primary screening hits, 
defined as any compound that substantially increased motor activity in response to light, 
comprised 269 potential hit compounds including 54 false positive solvent-treated controls (Fig. 
2.8). These potential hits were manually reviewed to prioritize the most promising hit 
compounds and remove false positives due to camera flickers and other technical errors, 
yielding 99 primary hits (Fig. 2.7). From these hits, 6 optovin analogues were removed, and a 
subset of 93 primary hits were reordered and retested (Fig. 2.7). Of these 93 primary hit 
compounds, 34 (36.56%) reproducibly increased light-induced motor activity in vivo, and 17 
compounds were selected as final hits following dose-response testing. An additional four 
compounds were included based on manual analysis identifying them as potential hits of 
interest for a final total of 21 hit compounds (Fig. 2.9, 2.7). 
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Figure 2.7 Hit screening and identification process 
Flowchart depicting the process of testing, screening, and identifying final set of hit compounds. 
Hits listed within each level represents the resulting number of hits from that level. 
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Figure 2.8 Large-scale screening identifies early hit compounds 
Two chemical libraries, containing a combined 30,656 structurally diverse compounds and 
8,163 negative DMSO controls, were tested against a battery containing a variety of light-based 
stimuli. Fold change in activity versus DMSO was calculated for each compound for stimuli of 
interest. Compounds that had at least one measured value with a fold change greater than 3σ 
(1.58) were selected for further retesting, from which 34 were selected for dose-response 
testing. n = 1 well per compound and 8163 wells DMSO; 8 fish/well. 
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Figure 2.9 Dose-response analysis finalizes hit set and identifies optimal doses 
Scatter plot showing -log10P values for selected stimuli of interest for each compound-treated 
well compared against the corresponding stimulus in DMSO-treated wells. The 34 compounds 
selected for dose-response analysis were tested at 2-fold intervals from 0.78125μM to 100μM 
against the screening battery. Seventeen unique compounds exceeded the significance 
threshold (horizontal line). n = 6 wells/test compound/dose, 368 wells DMSO, 118 wells optovin, 
and 96 wells with no treatment; 8 fish/well. Significance threshold corrected using Bonferroni. 
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Structural analyses revealed that the validated hit compounds included a wide variety of 
structures. These compounds clustered into at least 11 structural classes (Fig. 2.10, 2.11, 
Table 2.2). Unlike optovin, most of the novel hit compounds did not contain a rhodanine ring 
except compound 784. However, there were several other features of note. Though they did not 
cluster together, compounds 15951 (cluster 10) and 23002 (cluster 2) both have an 
adamantane group. Additionally, compounds 819 and 825 in cluster 5 both have a central, fused 
double thiazole along with distinct symmetry in each compound. Likewise, compounds in cluster 
6 all share a thienopyridine. Together, these data suggest that, like optovin, a subset of these 
novel compounds may also be photoactivated TRPA1 ligands, as the validated hit compounds 
reproducibly produce light-elicited behavioral excitation. Interestingly, the hit compounds 
included a variety of chemical structures, raising questions about their potential mechanisms of 
action and photoreactivity.  
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Figure 2.10 Hierarchical clustering identifies 11 structural classes 
Dendrogram depicting hierarchical clustering of hit compound structures.   
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Figure 2.11 Hit compound structures grouped by cluster  
Hit compound structures grouped by clusters identified via hierarchical clustering (cont’d on 
following page)  
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Figure 2.11 Hit compound structures grouped by cluster (cont’d) 
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 Table 2.2 Hit compound SMILES 
 
 
Compound ID SMILES
optovin Cc1cc(C=C2SC(=S)NC2=O)c(C)n1-c1cccnc1
53 CCn1c2ccc(Br)cc2c2nc3ccccc3nc21
99 COc1ccc2sc3ccccc3c(=O)c2c1
784 COc1cc(ccc1OCc2ccc(cc2)F)/C=C/3\C(=O)N(C(=S)S3)CC(=O)O
819 c12c(nc(s2)c2cc(c(O)cc2)OC)sc(n1)c1cc(OC)c(cc1)O
821 COc1ccc(cc1)C(=O)c2c(c3ccccc3o2)NC(=O)c4ccco4
822 Cc1c2c(nc(nc2sc1C(=O)c3ccccc3)c4ccccc4)N
823 CCN(CC)c1ccc(cc1)n2nc3cc(c(cc3n2)N)C
825 c1cc2c(c3c1[nH]c4c3CCCC4)non2
826 c12c(nc(s2)c2ccc(cc2)CC)sc(n1)c1ccc(cc1)CC
15951 Cc1[nH]nc(O)c1C1(C(C#N)C#N)C2CC3CC(C2)CC1C3
18771 O=C(CN1CCCCC1)Nc1cc(Cl)cc(Cl)c1
23002 O=C(Nc1ccc2c(c1)COC2=O)C12CC3CC(CC(C3)C1)C2
27514 O=C(Nc1ccc(Cl)c(Cl)c1)N1CCN(C2CCSCC2)CC1
27660 O=c1cc(O)c2sc3nc(-c4cccs4)cc(-c4cccs4)c3c2[nH]1
28491 O=c1cc(O)c2sc3nc(-c4ccc(Cl)cc4)cc(C(F)F)c3c2[nH]1
29342 O=c1nc(O)c2sc3nc(-c4ccc(Cl)cc4)cc(C(F)(F)F)c3c2[nH]1
30580 COc1ccccc1NC(=O)N1CCCC1c1ccc(Cl)cc1
31662 CC(O)c1cccc(Nc2nc(N3CCCC3)c3ccccc3n2)c1
32023 COc1ccc(Cn2ccc3nc4ccn(Cc5ccccc5)c(=O)c4cc3c2=O)cc1
32983 C=CCNc1nc(N2CCOCC2)nc2ccccc12
33714 CSc1ccccc1NC(=O)C1(c2ccccc2)CCOCC1
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Photoactivity of hit compounds greatly varies 
Previous studies have revealed that aspects of TRPA1-mediated photo-sensation involve 
photoreactivity. For example, TRPA1 is activated by photosensitizing agents in vitro33. 
Furthermore, optovin is a photoreactive compound25. Thus, we hypothesized that a subset of hit 
compounds would also be photoreactive. To answer this question, we measured a variety of 
photochemical properties including their absorbance, photostability after multiple irradiations, 
fluorescence, and phototoxicity. 
 
The absorbance studies revealed that most compounds displayed peak absorbance between 
wavelengths ~310 and 410nm (Fig. 2.12, 2.13). For example, 99, 784, and 28491 displayed 
peak absorbance at 390nm, 410nm, and 350nm, respectively (Fig. 2.12, 2.13). Several 
compounds produced two absorbance peaks including 53, 825, and 27660 (Fig. 2.12, 2.13). By 
contrast, none of the novel hit compounds had a maximum absorbance above 410nm (Fig. 
2.12, 2.13), while six compounds (15951, 18771, 27514, 30580, 31662, 33714) did not display 
absorbance at any wavelength tested. Optovin absorbance, by comparison, occurs at 470nm, 
which is an outlier compared to the absorption range of the hit compounds (Fig. 2.12, 2.13). The 
DMSO-treated negative controls displayed no absorption at any wavelength in the tested range 
(Fig. 2.12, 2.13). 
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Figure 2.12 Hit compound absorbance  
Bar plot showing the magnitude (y-axis) of light absorbance of hit compounds. Where more than 
one absorbance peak was detected, the bar for the secondary peak is colored in orange. 
Absorbance wavelengths (nm) are labeled at the top of each bar. 
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Figure 2.13 Hit compound raw absorbance data 
Absorbances (measured in absorbance units) of hit compounds dissolved in egg water.  
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As a measure of photostability, we determined if the compounds changed absorbance after 
multiple irradiations. In 17 of 21 hit compounds, the maximum change in absorbance was equal 
to or less than 0.10 absorbance units, a change that was relatively minor (Fig. 2.14, 2.15, Table 
2.3). For example, 7 compounds (including 53, 784, 825, 15951, 18771, 23002, 29342) 
increased absorbance by 0.10 absorbance units or less (Fig. 2.14, 2.15, Table 2.3). Similarly, 
10 compounds (including 99, 819, 821, 823, 826, 27514, 30580, 32032, 32983, 33714) 
decreased absorbance by less than 0.10 absorbance units (Fig. 2.14, 2.15, Table 2.3). By 
contrast, multiple irradiations greatly increased the absorbance of compounds 28491 and 
31662, rising by 0.55 and 0.34 absorbance units, respectively, while absorbance in compounds 
822 and 27660 was reduced by 0.11 and 0.14, respectively (Fig. 2.14, 2.15, Table 2.3). 
Comparatively, the 0.12 absorbance unit reduction of peak absorbance in optovin occurred at 
470nm, while DMSO demonstrated no change (Fig. 2.14, 2.15, Table 2.3).  
 
Fluorescence studies revealed that most hit compounds were not strongly fluorescent (Table 
2.4). For example, 14 compounds (53, 784, 819, 825, 826, 15951, 18771, 23002, 27514, 29342, 
30580, 32023, 32983, 37714) had excitation/emission wavelengths of 350nm/395nm (Table 
2.4). By contrast, a subset of compounds showed measurable emissions. For example, 
compounds 821 and 822 emitted in the blue range (455nm and 475nm, respectively) (Table 
2.4).  Compounds 99, 823, 27660 (all 535nm) and 28491 (515nm) emitted in the green range 
(Table 2.4). One outlier was compound 99, which displayed a maximum excitation wavelength 
at 410 nm (Table 2.4). Importantly, neither optovin nor DMSO were strongly fluorescent, 
displaying maximum excitation/emission at 350nm/395nm (Table 2.4).  
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Figure 2.14 Changes in hit compound absorbance following exposure to violet light 
Bar plot showing the maximum change in absorbance (y-axis) following multiple irradiation. 
Following an initial baseline absorbance measurement, compounds were exposed to violet light 
for varying lengths of time between 5 and 1200s (20 min.), after which absorbance was 
measured again. Max delta refers to the greatest change in absorbance at one wavelength 
between any two timepoints. Absorbance wavelengths (nm) are labeled at the top of each bar. 
 
 41 
 
 
Figure 2.15 Hit compound raw absorbance data following multiple irradiation 
Absorbances (measured in absorbance units) of hit compounds dissolved in egg water. 
Following an initial baseline absorbance measurement, compounds were exposed to violet light 
for varying lengths of time between 5 and 1200s (20 min.), after which absorbance was 
measured again. 
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Table 2.3 Values for max delta following multiple irradiation 
Actual values for max delta as shown in Fig. 2.14. Max delta refers to the greatest change in 
absorbance at one wavelength between any two timepoints. Change is calculated using the 
earlier timepoint as a baseline. 
 
 
 
Compound ID Max delta Wavelength (nm)
53 0.0057 250
99 -0.0546 250
784 0.0577 410
819 -0.0078 350
821 -0.0643 370
822 -0.1086 270
823 -0.041 370
825 0.0451 250
826 -0.0029 370
15951 0.0239 250
18771 0.0463 250
23002 0.0377 290
27514 -0.0878 250
27660 -0.137 310
28491 0.5482 290
29342 0.0943 350
30580 -0.0156 330
31662 0.3354 250
32023 -0.02 330
32983 -0.0588 250
33714 -0.0283 250
optovin -0.1233 470
DMSO -0.0018 250
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Table 2.4 Excitation/emissions experiments showed that most compounds are not 
strongly fluorescent 
For each compound, the maximum excitation and emission wavelengths were identified. 
Outliers that excite/emit at wavelengths other than 350nm/395nm are highlighted in red. 
 
 
Compound ID Excitation wavelength
Emission 
wavelength
53 350 395
99 410 535
784 350 395
819 350 395
821 390 455
822 390 475
823 350 535
825 350 395
826 350 395
15951 350 395
18771 350 395
23002 350 395
27514 350 395
27660 370 535
28491 350 515
29342 350 395
30580 350 395
31662 350 395
32023 350 395
32983 350 395
33714 350 395
Optovin 350 395
DMSO 350 395
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As another measure of photoreactivity, we determined if the compounds produced phototoxicity. 
To this end, we tracked the activity of treated fish for 12 hours. During the first six, larvae were 
exposed to light stimulus, after which activity was tracked for an additional six hours. Length of 
survival/time of death was calculated quantitatively by analysis of the MI traces. These 
phototoxicity studies revealed that many of the hit compounds (12/21) demonstrated some level 
of phototoxicity under violet and blue wavelengths (Fig. 2.16, Table 2.5, 2.6). For example, four 
compounds (including 53, 27660, 28491, and 29342) were significantly phototoxic under both 
violet and blue wavelengths, and seven compounds (including 99, 819, 821, 822, 823, 826, 
32983) were significantly phototoxic under only violet wavelengths. Other compounds 
demonstrated a trend towards phototoxicity, though not at significant levels. These include 99 
and 819, which have some blue wavelength toxicity in addition to their violet wavelength toxicity, 
and 32023, which has only blue wavelength toxicity (Fig. 2.16, Table 2.5, 2.6). Additionally, two 
compounds (53 and 28491) showed a dose-dependent sensitivity to different wavelengths, with 
higher doses conferring phototoxicity under both violet and blue wavelengths, while lower doses 
conferred phototoxicity only in the presence of violet wavelengths (Fig. 2.16, Table 2.5, 2.6). 
Phototoxicity most often occurred within the first two hours of light exposure and death rarely 
occurred under the green, red, or no stimulus conditions (Fig. 2.16, Table 2.5, 2.6). While some 
fish did die under red and green light conditions, these tended to be single replicates, and death 
occurred relatively late in the experiment (>8 hours). Two compounds (30580 and 33714) were 
significantly toxic under all conditions, including when no stimulus was present, while another 
two, 15951 and 31662, trended towards general toxicity. Interestingly, in compound 30580, 
which was shown to be generally toxic, the presence of red light significantly increased survival 
above the no stimulus condition (Fig. 2.16, Table 2.5, 2.6). A small number of hit compounds (5 
out of 21) were not phototoxic under any conditions including 784, 825, 18771, 23002, and 
27514. Likewise, optovin and low dose (25μM and 100μM) eugenol were not phototoxic, though 
optovin demonstrated a slight trend towards phototoxicity under violet wavelengths.  
 45 
Importantly, solvent-treated negative controls were not toxic under any conditions, independent 
of stimulus wavelength. Furthermore, eugenol-treated (300μM) positive controls were toxic 
under all conditions, independent of stimulus wavelength (Fig. 2.16, Table 2.5, 2.6). 
 
Together, these photoreactivity data suggest that although a subset of hit compounds were 
photoreactive, this photoreactivity was difficult to measure by absorbance, multiple irradiation, 
and fluorescence. However, most of the hit compounds were phototoxic to some degree. These 
data suggest that many of the hit compounds are photoreactive, raising questions about their 
target and phenotypic specificity.  
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Figure 2.16 Survival time following hit compound treatment and exposure to varying light 
wavelengths 
Plot depicting the survival time of hit compound-treated larvae exposed to varying wavelengths 
of light. The activity of treated fish was tracked for 12 hours. During the first six, larvae were 
exposed to light stimulus, after which activity was tracked for an additional six hours. Marker 
color indicates stimulus wavelength (no stimulus condition indicated by black). The size of the 
marker indicates the number of wells, with the position of the marker along the x-axis indicating 
the time at which those wells were considered to have died. Time of death was determined by 
identifying the last 5 minute window in which the standard deviation of activity was equal to or 
less than the overall standard deviation of activity in the 300μM eugenol-treated positive 
controls. Wells that did not meet this criterion within the 12 hour period were considered to have 
survived. n = 12 wells per stimulus per compound; 8 fish/well. 
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Table 2.5 Length of survival with exposure to light 
Average length of survival (min.) during the phototoxicity experiment described in Fig. 2.16.  
n = 12 wells per stimulus per compound; 8 fish/well. *p < 0.05. 
 
 
Compound ID Violet Blue Red Green No stimulus
Group
53 (0.78125µM) 61* ±13.24 720 720 720 720 B
53 (100µM) 8* ±0.97 24* ±7.88 720 720 713 ±5.92 A
99 (50µM) 7* ±0.94 647 ±49.28 720 707 ±12.92 720 A
784 (100µM) 720 720 720 720 720 A
819 (1.5625µM) 16* ±1.72 720 720 720 720 A
819 (6.25µM) 8* ±1.44 677 ±43.33 720 720 720 A
821 (3.125µM) 190* ±92.27 720 719 ±1.25 705 ±14.58 720 B
822 (3.125µM) 17* ±0.94 720 720 720 720 B
823 (3.125µM) 6* ±0.56 720 720 720 720 B
823 (6.25µM) 9* ±2.29 720 720 720 720 A
825 (3.125µM) 720 720 720 720 720 B
826 (100µM) 215* ±67.42 720 720 720 720 B
15951 (1.5625µM) 710 ±7.1 625 ±52.91 704 ±11.06 679 ±18.98 693 ±16.86 C
18771 (0.78125µM) 720 720 720 720 720 C
23002 (1.5625µM) 720 720 720 720 720 C
27514 (6.25µM) 720 720 720 720 720 D
27514 (50µM) 719 ±0.83 720 720 719 ±0.83 720 D
27660 (25µM) 33* ±3.11 233* ±51.38 720 720 720 B
27660 (100µM) 65* ±39.53 65* ±3.4 720 720 720 B
28491 (6.25µM) 68* ±8.4 720 720 720 720 B
28491 (25µM) 35* ±4.15 425* ±89.33 720 720 720 B
29342 (50µM) 38* ±7.52 63* ±18.04 715 ±5.42 720 720 B
29342 (100µM) 22* ±1.14 40* ±5.59 720 683 ±24.79 719 ±1.25 B
30580 (25µM) 637 ±42.77 653 ±51.48 713* ±4.86 585 ±47.89 579* ±60.79 D
31662 (25µM) 608 ±62.57 720 720 560 ±84.03 675 ±45 D
32023 (0.78125µM) 720 560 ±83.58 720 720 720 B
32983 (25µM) 15* ±1.14 720 720 720 713 ±7.5 B
33714 (50µM) 461 ±59.32 463 ±67.61 681 ±16.89 592 ±39.66 602* ±35.74 D
optovin (6.25µM) 604 ±0 720 720 720 720 A
eugenol (25µM) 720 720 720 720 720 --
eugenol (100µM) 720 720 720 720 720 --
eugenol (300µM) 1 ±0.65 1 ±0.65 2 ±0.71 2 ±0.71 3* ±1.31 --
DMSO 720 ±61.83 720 720 720 720 --
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Table 2.6 P-values for length of survival with exposure to light 
P-values for the average length of survival (min.) during the phototoxicity experiment described 
in Fig. 2.16. For the violet, blue, red, and green conditions, p-values were calculated using the 
same compound with no stimulus exposure as the control. For the no stimulus condition, p-
values were calculated versus DMSO with no stimulus exposure as the control. A p-value of 0 
indicates no difference from the control. n = 12 wells per stimulus per compound; 8 fish/well. 
 
 
 
Compound ID Violet Blue Red Green No stimulus (vs DMSO) Group
53 (0.78125µM) 2.67E-14 0 0 0 0 B
53 (100µM) 3.36E-19 8.92E-26 0.231308 0.231308 0.231308 A
99 (50µM) 2.62E-27 0.167004 0 0.338801 0 A
784 (100µM) 0 0 0 0 0 A
819 (1.5625µM) 2.36E-24 0 0 0 0 A
819 (6.25µM) 2.96E-25 0.338801 0 0 0 A
821 (3.125µM) 0.000129499 0 0.338801 0.338801 0 B
822 (3.125µM) 3.06E-27 0 0 0 0 B
823 (3.125µM) 8.97E-30 0 0 0 0 B
823 (6.25µM) 4.85E-23 0 0 0 0 A
825 (3.125µM) 0 0 0 0 0 B
826 (100µM) 1.2E-05 0 0 0 0 B
15951 (1.5625µM) 0.376838 0.242708 0.611412 0.582503 0.142008 C
18771 (0.78125µM) 0 0 0 0 0 C
23002 (1.5625µM) 0 0 0 0 0 C
27514 (6.25µM) 0 0 0 0 0 D
27514 (50µM) 0.338801 0 0 0.338801 0 D
27660 (25µM) 2.02E-21 1.25E-06 0 0 0 B
27660 (100µM) 4E-09 9.08E-21 0 0 0 B
28491 (6.25µM) 2.02E-16 0 0 0 0 B
28491 (25µM) 5.02E-20 0.0071086 0 0 0 B
29342 (50µM) 3.67E-17 8.06E-13 0.338801 0 0 B
29342 (100µM) 6.01E-44 6.41E-20 0.338801 0.18124 0.338801 B
30580 (25µM) 0.445117 0.367518 0.0497961 0.936401 0.0408208 D
31662 (25µM) 0.397289 0.338801 0.338801 0.244318 0.338801 D
32023 (0.78125µM) 0 0.0819291 0 0 0 B
32983 (25µM) 7.35E-18 0.338801 0.338801 0.338801 0.338801 B
33714 (50µM) 0.0569664 0.087651 0.0628211 0.853166 0.0070885 D
optovin (6.25µM) 0.0867941 0 0 0 0 A
eugenol (25µM) 0 0 0 0 0 --
eugenol (100µM) 0 0 0 0 0 --
eugenol (300µM) 0.404312 0.404312 0.582379 0.582379 9.09E-26 --
DMSO (1µM) 0 0 0 0 N/A --
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Hit compounds cluster into four phenotypic classes 
Previous research has shown that compounds with similar behavioral profiles tend to act via 
similar molecular mechanisms, a key principle of phenotype based genetic screens34. 
Therefore, we wondered if the hit compounds produced distinct behavioral sub-classes. To 
answer this question, we analyzed their behavioral profiles using a multi-step process. First, 
optimal doses for each compound were selected by identifying the concentration of each 
compound that produced the maximum increase in motor activity (Fig. 2.9). At this optimal 
concentration, all the hits were then tested in a behavioral battery designed to emphasize 
potential phenotypic differences. To visualize these differences, the behavioral profiles were 
analyzed by tSNE (Fig. 2.17) and pairwise clustering (Fig. 2.18), then inspected by a manual 
analysis (Fig. 2.19, 2.20). 
 
These analyses revealed that the behavioral profiles could be classified into four main groups 
(Groups A-D), with DMSO-treated negative control wells clustered in a fifth group. The first 
group, Group A, included optovin and 4 additional compounds (53, 99, 784, 819) (Fig. 2.21, 
2.22, Table 2.7). These compounds produced phenotypes similar to the optovin response, 
characterized mainly by the P1 spike, which occurs at the onset of stimulus activity and is very 
distinctive (Fig. 2.19, 2.21) with the P2 spike sometimes but not always present (Fig. 2.18). The 
P2 spike, if present, tends to be an elevated level of activity compared to background levels 
(during the no-stimulus portions of the battery), but is generally not greater than DMSO activity 
(Fig. 2.21, 2.22). Referring back to the tSNE analysis (Fig. 2.17), category A compounds can be 
further split into “toxic” and “non-toxic” subgroups. However, because the B compounds likewise 
have varying levels of toxicity but are more closely grouped with each other rather than the toxic 
A compounds, this suggests that something beyond toxicity - most likely the P1 spike - 
separates the toxic A and B compounds. 
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Figure 2.17 tSNE analysis of full activity traces reveals phenotypic clusters 
tSNE analysis of full activity traces recorded from hit compound-treated larvae identifies clusters 
of compounds with similar phenotypes. Retroactive labelling following further analysis revealed 
that these groups closely correlated with the identified phenotypic clusters. n = 6 wells optovin, 
6 wells DMSO, 3 wells per hit compound; 8 fish/well. 
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Figure 2.18 Pairwise scatter plot identifies behavioral phenotype signatures 
Pairwise scatter plots identify the phenotypic features that best separate the groups identified in 
the tSNE analysis. Light responses for all compounds were first broken down into the optovin-
defined phases (pre, P1, P2 and post, with P3 not represented in this test battery). Following 
pairwise comparisons, it was revealed that the P1 vs. DMSO and P2 vs. DMSO fold change 
measurements created the greatest separation between compounds. Retroactive labelling 
demonstrated that the presence of P1- or P2-like phases most strongly differentiated the 
A/C and B/D groups. n = 6 wells optovin, 6 wells DMSO, 3 wells per hit compound; 8 fish/well. 
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Figure 2.19 Heatmap analysis and clustering further define phenotypic groupings 
As labeled, branch 1, which includes optovin, is defined by a very strong initial spike of activity 
in the first few seconds of the stimulus, while branch 2 is characterized by increased activity 
throughout the stimulus. The phenotype observed in branch 3 has characteristics of both 1 and 
2. Branches 4 and 5 display more anomalous phenotypes, with branch 4 displaying an increase 
of activity beginning during the stimulus and continuing through the post-stimulus period, while 
activity in branch 5 shows little consistency. n = 6 wells optovin, 6 wells DMSO, 3 wells per hit 
compound; 8 fish/well. 
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Figure 2.20 MI heatmap analysis and clustering for blue, red, and green wavelengths 
Treated fish were exposed to either blue (460nm), red (660nm), or green (523nm) light. n = 6 
wells optovin, 6 wells DMSO, 3 wells per hit compound; 8 fish/well. (cont’d on next page) 
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Figure 2.20 MI heatmap analysis and clustering for blue, red, and green wavelengths 
(cont’d) 
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Figure 2.21 Representative MI traces for the four phenotypic subgroups 
MI traces illustrate differences between the four behavioral phenotypes: A (most similar to 
optovin with a distinct P1 spike), B (purple light-sensitive with a P2-like response), C (on/off light 
responsive), and D (not optovin-like). Examples of each are shown here, including two 
examples for group D (red traces represent hit compounds, gray traces represent DMSO). 
Examples A, C, D1, D2: n = 3 wells; 5 fish/well. Examples for optovin, B: n = 3 wells; 8 fish/well. 
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Table 2.7 Classification of hit compounds for all wavelengths 
 
 
 
Compound ID 
(dose, µM) Violet Blue Green Red
optovin A A
53 (0.78125) B B
53 (100) A A
99 (50) A
784 (100) A A
819 (1.5625) A
819 (6.25) A
821 (3.125) B
822 (3.125) B
823 (3.125) B
823 (6.25) A
825 (3.125) B
826 (100) B
15951 (1.5625) C C C C
18771 (0.78125) C C C C
23002 (1.5625) C C C C
27514 (6.25) D D D D
27514 (50) D D D D
27660 (25) B B
27660 (100) B B
28491 (6.25) B D
28491 (25) B D D D
29342 (50) B B D
29342 (100) B B D D
30580 (25) D D D D
31662 (25) D A D D
32023 (0.78125) B
32983 (25) B B D D
33714 (50) D D D
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Figure 2.22 MI traces for A compounds.  
The A compounds, including optovin, are characterized by a distinct spike of activity at the 
beginning of the stimulus. The P2 spike is sometimes but not always present.  
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The second group, Group B, included 13 compounds (Fig. 2.21, 2.23, Table 2.7). These 
compounds produced phenotypes that were characterized by large P2 spikes, the absence of 
P1 spikes (Fig. 2.18, 2.21), and consistently elevated activity while the stimulus is ongoing. This 
response is usually 1.5- to 2-fold higher than DMSO and continues for the duration of the 1 
minute light stimulus. Notably, in contrast to the category A response, the first few seconds of 
the response (the P1 “spike” seen in category A) are not increased compared to the rest of the 
response (Fig. 2.19, 2.21). Similar to category A, post-stimulus response is approximately the 
same or below DMSO-induced response. 
 
The third group, category C, included 3 compounds (Table 2.7) that displayed phenotypes very 
similar to those of optovin, but which can be distinguished by the presence of a second spike 
when the stimulus ends (Fig. 2.19, 2.21, 2.24). In this “on/off” (ONOFF) response, when the 
stimulus is first activated, a sharp spike of activity occurs, similar to the category A response. 
This similarity likely contributed to the inclusion of these compounds in the same clusters as 
category A compounds (Fig. 2.17, 2.18, 2.19). However, unlike the category A response, when 
the light stimulus is turned off, a second distinct activity spike is observed. Activity levels 
between the two spikes while the stimulus is ongoing are generally lower than DMSO, while 
post-stimulus activity is more variable than in both A and B, with occasional small spikes of 
activity. The three compounds that induce this behavior (15951, 18771, 23002) do so in 
response to all tested wavelengths of the light stimulus (Fig. 2.19, 2.20, Table 2.7). 
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Figure 2.23 MI traces for B compounds 
B group compounds are characterized by large P2 spikes and the absence of P1 spikes. Activity 
is consistently elevated while the stimulus is ongoing. (cont’d on next page) 
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Figure 2.23 MI traces for B compounds (cont’d)
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Figure 2.24 MI traces for C compounds 
Group C compounds display a distinct “on/off” response. While the initial sharp spike of activity 
is very similar to that of the A group compounds, C group compounds also induce a second 
distinct activity spike when the light stimulus is turned off. 
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The fourth group, category D, included 4 compounds that generally increased overall motor 
activity (Fig. 2.19, 2.21, 2.25). While the responses in categories A, B, and C are to some extent 
optovin-like, category D consists of non-optovin-like light-dependent behaviors. In general, while 
these behaviors are affected by the light stimulus, the immediate response to a stimulus is only 
slightly higher than in controls, but the slight increase in activity continues even after the 
stimulus ends. Additionally, inter-stimulus activity levels tend to be more variable than in the first 
three phenotypic categories. 
 
Interestingly, of the compounds tested, some compounds (53, 819) induced different types of 
activity at different doses, where at low doses the response was more similar to the B group 
compound response, and at higher doses the response was more similar to those induced by 
the A group (Table 2.7, Fig. 2.22, 2.23). Furthermore, both long- and short-term toxicity of these 
compounds is mixed (Fig. 2.16). In addition to violet light, blue, red, and green light stimuli were 
tested as well (Fig. 2.20, Table 2.7), revealing that similar patterns of behavior (A, B, C, or D) 
could be induced by these wavelengths, but not necessarily by the same compounds. For many 
compounds, blue light induced the same type of behavior in fish as violet light, but for others, 
blue light induced a different response or none at all (Fig. 2.20, Table 2.7). Red and green light 
in combination with hit compound treatments were less likely to elicit any response whatsoever, 
and those that did tended to induce category C or D behaviors (Fig. 2.20, Table 2.7). 
 
Since the hit compounds cluster into distinct phenotypic subclasses, these data suggest that 
each subclass may represent a different biological mechanism. For example, one of the most 
distinct clusters, the compounds that produce the ONOFF phenotype, may depend on different 
molecular targets than either optovin or the other hit compounds. 
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Figure 2.25 MI traces for D compounds 
The D group consists of compounds that generally increase activity in a light-dependent but 
non-optovin-like manner. While these behaviors are affected by the light stimulus, the 
immediate response to a stimulus is only slightly higher than in controls, and the increase in 
activity continues even after the stimulus ends. Additionally, inter-stimulus activity levels tend to 
be more variable than in the other three phenotypic categories. 
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A subset of hit compounds act via TRPA1b 
Previous studies have shown that optovin produces non-visual TRPA1-mediated 
photosensation25. However, it remains unclear if any of the novel hit compounds depend on 
either vision or TRPA1. To answer this question, we analyzed the effects of mutations affecting 
TRPA1b, as well as ATOH7, a gene that is required for the development of retinal ganglion cells 
and the loss of which results in complete blindness35. 
 
Group A and B compounds, which induced activity most similar to that of optovin, were 
generally found to be dependent on TRPA1b (Fig. 2.26, 2.27). Conversely, group C activity is 
dependent on ATOH7, but not TRPA1b (Fig. 2.26, 2.27, 2.28). Group D activity did not depend 
on TRPA1b, but the dependence of this group as a whole on ATOH7 is unclear (Fig. 2.26, 2.27, 
2.28). From the A group, P1 spiking was abolished in the TRPA1b mutants for four out of the 
five hit compounds. The last compound likewise followed a similar trend, though the change in 
response did not reach significance (Fig. 2.26, 2.27). Similarly, the optovin response was 
abolished in TRPA1b mutants. Conversely, treatment using the A group compounds in ATOH7 
KO fish did not result in a reduced response (Fig. 2.28). Similarly, in Group B, P2 spiking was 
also abolished in TRPA1 mutants for six out of eleven compounds, but not in ATOH7 or WT 
controls (Fig. 2.26, 2.27, 2.28). By contrast, for the two tested group C compounds, ONOFF 
was abolished in ATOH7 mutants. However, this did not occur in WT controls or in TRPA1 KOs, 
in which all three group C compounds were tested (Fig. 2.26, 2.27, 2.28). Finally, in Group D, 
no compounds induced a significantly different response in TRPA1bKO fish compared to the 
WT fish. Two group D compounds were tested in the ATOH7 fish; of these, one showed a 
significant decrease in response (Fig. 2.26, 2.27, 2.28). Together, these data suggest that 
compounds in Group A and B, like optovin, produce non-visual TRPA1-mediated 
photosensation. By contrast, the compounds in group C act on visual pathways.  
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Figure 2.26 Example MI traces demonstrating TRPA1b or ATOH7 dependence  
Example traces illustrate the effect of hit compounds from different phenotypic groups in WT, 
TRPA1b KO, and ATOH7 KO fish compared to background-matched controls. n = 3 wells; 5 
fish/well. *p < 0.05.
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Figure 2.27 A subset of hit compounds act via the TRPA1b receptor 
Bar plots depict the response fold change of WT and TRPA1b KO fish treated with hit 
compounds against DMSO-treated background-matched larvae. n= 14 wells per compound per 
genetic background for DMSO and optovin, 3 wells per compound per genetic background for 
hit compounds, 2 wells per compound per genetic background for no treatment; 5 fish/well. 
Error bars represent SEM. *p<0.05. 
(A) A group compounds; response measured during P1 phase.  
(B) B group compounds; response measured throughout the first stimulus (1 min).  
(C) C/D group hit compounds; response measured throughout the first stimulus (1 min). 
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Figure 2.28 A subset of hit compounds requires ATOH7   
Mutation of the atoh7 gene in zebrafish results in the complete elimination of the retinal ganglion 
cells, rendering the fish blind. In order to determine whether the compound effects were vision-
dependent, the hit compounds were tested in ATOH7 KO fish. n = 3 wells per compound per 
genetic background for hit compounds except 784, 6 wells per genetic background for 784, 8 
WT and 7 ATOH7 KO wells for optovin and DMSO, 12 WT and 1 ATOH7KO wells for no 
treatment; 5 fish/well. Error bars represent SEM. *p<0.05. 
(A) A group compounds; response measured during P1 phase.  
(B-D) B, C, and D group compounds, respectively; response measured throughout the first 
stimulus. 
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DISCUSSION 
 
We demonstrate here that a wide variety of structurally diverse novel compounds can produce 
non-visual photosensation via TRPA1 in zebrafish (Fig. 2.29). Evidence suggests that these 
compounds are photoreactive and depend on TRPA1b, and that they induce different patterns 
of behavioral phenotypes. These observations extend our understanding of the pharmacology of 
TRPA1-mediated non-visual photosensation beyond compounds structurally related to optovin. 
 
Light responsive compounds demonstrate structural diversity 
Although previous studies had identified optovin analogues36, it was unclear whether  TRPA1-
mediated non-visual photosensation also occurred with other, more structurally diverse 
compounds. Through this study, we have demonstrated that there are multiple novel 
compounds with structural and photochemical properties that differ greatly from those of 
optovin, but yet are similarly able to induce motor activity in response to light. Previously, 
optovin’s photoactive properties have been linked to its rhodanine ring. However, the majority of 
photoactivatable compounds identified here do not contain this moiety, suggesting that a 
rhodanine ring may not be required to confer TRPA1-mediated non-visual photosensation.  
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Figure 2.29 Novel compounds produce non-visual photosensation via TRPA1 
For the majority of known TRPA1 agonists such as AITC or CA, binding to the allosteric nexus 
of TRPA1 will  open the channel. However, for optovin and the novel optovin-like compounds 
identified in this screen, channel opening requires both binding and exposure to light, most 
commonly in the violet or blue wavelengths.  
 
 70 
Hit compound phenotypes cluster into four distinct categories 
Phenotypically, we observed that the compound responses to violet light tended to cluster into 
four main categories. Groups A and B comprised compounds that induce optovin-like 
phenotypes, with A defined by an initial sharp spike of activity (equivalent to P1 in optovin) and 
B defined by a more gradual increase in activity (equivalent to P2). This split was unexpected, 
as we initially believed that all optovin-like compounds would have a similar behavioral profile. 
One potential explanation for this is that the hit compounds - or, possibly, their light-activated 
configuration - may have varying affinities for TRPA1. Compounds with higher affinities would 
bind to and activate more channels, thus rapidly inducing a large amount of activity via the 
receptor, while compounds with lower affinities would not bind as frequently, resulting in fewer 
channel openings and therefore slower, more sustained activity that does not reach as high of a 
magnitude. Likewise, compound availability may be a limiting factor in receptor binding and may 
be affected by blood protein binding37 or distribution into the tissues38, or, if the compounds are 
acting on TRPA1 receptors in the brain, slow or limited passage across the blood-brain barrier39. 
This is supported by the observation that several of the compounds tested at multiple doses (53, 
823) switch from B-type activity at the lower dose to A-type activity at the higher, where an 
increased dose would result in more of the compound being available to bind to receptors40. 
However, other compounds did not display A-type activity at any tested dose. In these cases, a 
possible explanation for B-type activity is that while the compounds may be readily available in 
their inactive state, they may undergo a slower conversion to the light-activated binding form, 
thus accounting for the relatively slower increase to maximum activity levels observed with B 
compounds.  
 
Conversely, group C and D compounds did not induce optovin-like phenotypes. Group C 
compounds, despite their similarity to the A group due to the initial P1-like spike of the 
phenotype, also induced a secondary, smaller spike when the stimulus turned off, 
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demonstrating a novel mode of light response. Group D consisted of compounds that induced 
phenotypes that were not similar to optovin and did not fit with the other categories. However, 
as these groups were not shown to act via TRPA1, it is difficult to speculate on their 
mechanisms.  
 
Optovin-like compounds demonstrate the greatest response to blue and violet 
wavelengths 
In order to determine whether the light-induced phenotypes were specific only to violet light,  we 
also tested the response to blue, red, and green wavelengths and categorized them using the 
same groups as for the violet-light response. In accordance with the observation that optovin 
also demonstrates a strong response to blue light, many of the A and B group compounds 
likewise respond to blue light stimuli, and for each compound the blue light activity type 
resembles that of the violet light. Considering all light dependent activity, we observed fewer 
responses to green and red wavelengths. This is in line with previous research41, as light in 
these wavelengths carry less energy than light in blue or violet, and therefore would possess 
less energy to contribute to structural changes.  Because of this, it would be useful to perform a 
screen based on blue light activity to further probe the relationship between compound, 
wavelength, and receptor, and to identify whether blue light sensitivity exists independent of 
violet light sensitivity.  
 
Interestingly, we observed that C and D compounds demonstrated activity in response to all four 
wavelengths.  This suggests that both the responses of C compounds, whose activity is clearly 
light-dependent, and most D type compounds, whose activity is more generally unspecific, are 
more of a generalized, non-wavelength-specific light response.  
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Finally, we also noted that several compounds responded differently to the four wavelengths; for 
example, compound 32983 showed B type activity in blue and violet, but D type activity in red 
and green. For compounds shown to require TRPA1b (28491, 29342), it is possible that these 
may have off-target effects that are either suppressed during blue/violet stimuli or that are 
activated only in response to green/red light. For other compounds that are not TRPA1b 
dependent (31662), or whose TRPA1b status is unclear (32983), their activity may be due to a 
completely different receptor whose light-dependent activity has yet to be identified, or the 
activity may in fact be TRPA1b dependent, but in wavelengths other than violet. While in depth 
testing of responses to all wavelengths was beyond the scope of this study, this represents an 
intriguing direction for understanding the role different wavelengths play in light-dependent, 
small-molecule-induced behaviors. 
 
Absorbance and fluorescence of hit compounds varies greatly 
In addition to their structural and phenotypic features, we also investigated several 
photochemical properties of these compounds to determine if there were features that were 
common to all light-activated compounds. Though the wavelength at which absorbance 
occurred varied, optovin and all A and B group compounds exhibited some degree of 
absorbance. C and D compounds, however, did not demonstrate any absorbance. Together, 
this suggests that absorbance is required for light-dependent activation of TRPA1.  
 
Prior exposure to violet light (for time periods ranging from 5 to 1200 seconds) had either no 
effect or reduced absorption on most hit compounds and optovin, which was expected due to 
the possibility of bleaching or non-reversible light-dependent structural changes. Interestingly, in 
some compounds (28491, 29342, 31662), prior exposure in fact greatly increased absorption, 
suggesting that the addition of light energy induced structural changes that increased the 
likelihood of energy absorption. The degree by which absorption changed did not seem to 
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correlate to baseline absorbance (t0). Some compounds that demonstrated baseline 
absorbance showed very little change, while some compounds that did not (C group, 27514, 
31662) were affected by multiple exposures to light, with one (31662) surprisingly showing a 
very large increase. Generally, the wavelengths at which peak absorbance occurred were most 
affected by multiple irradiation, but this was not always the case. It remains unclear if changes 
in absorption, whether increasing or decreasing, are linked to the identified behavioral 
phenotype groups; for example, whether an increase in absorption resulting from prior violet 
light exposure would allow compounds not in groups A or B to induce A- or B-type activity.  
 
Finally, the majority of hit compounds and optovin, as well as the DMSO control, did not 
demonstrate notable maximum excitation or emission wavelengths (Table 2.4). Interestingly, 
outlier compounds were all found to be in either Group A or Group B. This suggests that there 
may be two different mechanisms behind the optovin-like response - one that involves 
photoreactivity, and one that occurs in the absence of it. For the Group C and Group D 
compounds, however, photoreactivity does not seem to be important.  
 
Phototoxicity is wavelength dependent 
Surprisingly, we noticed that exposure to violet and blue wavelengths significantly increased 
toxicity in many instances. Following the development of an experiment to test if light 
wavelength had an effect on compound toxicity, we found that this was indeed the case for 
many compounds following violet and blue light exposure, suggesting that these compounds are 
inert or mostly inert until activation by specific wavelengths. No compounds demonstrated 
significant increased toxicity following exposure to green or red wavelengths (compared to the 
no stimulus control), and baseline toxicity was observed in only two compounds (increased 
toxicity in the no stimulus control compared to the no stimulus DMSO control). Intriguingly, in 
one compound that displayed baseline toxicity (30580), exposure to red light actually increased 
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survival time, suggesting a protective effect that warrants further investigation in future studies. 
Based on these experiments, we believe that the energy provided by violet or blue light is 
necessary for the conversion of these compounds to their active form, which then allows them 
to bind to receptors and induce an effect. Potentially, when these receptors are continually 
activated for long periods of time, their effect eventually becomes toxic. As many of the 
compounds that demonstrated increased toxicity were shown to be TRPA1b dependent, it is 
therefore possible that this receptor is TRPA1b. Future iterations of these experiments utilizing 
TRPA1bKO fish will help to confirm this and to determine the mechanism of toxicity.  
 
Optovin-like hits are TRPA1b dependent 
In this study, TRPA1b dependence was observed in many of the A and B compounds, but not in 
any of the C and D compounds. To confirm TRPA1-dependence, we developed a line of 
TRPA1b KO zebrafish and assessed if their activity matched that of wild-type fish following 
treatment and stimuli exposure. Additionally, to determine if any of the induced behaviors were 
vision-dependent, we obtained zebrafish with a mutation in atoh7, which causes the complete 
loss of retinal ganglion cells and results in completely blind fish. Of the 14 A and B group 
compounds, 8 demonstrated a significant loss of phenotype in the TRPA1b KO fish, with several 
others approaching significance. However, of the A and B group compounds tested in ATOH7 
KO fish, loss of vision did not have an effect on this behavior. Conversely, TRPA1b dependence 
was not observed in any of the C and D compounds. However, of the compounds tested, loss of 
vision resulted in loss of the phenotypes induced by three compounds in this group (C: 15951, 
23002; D: 27514). Taken together, these results indicate that while some compound induced 
behaviors, especially those most similar to optovin-induced behaviors, are non-visual and are 
mediated by TRPA1b photosensation, others are acting through different receptors and 
mechanisms. Of these, the C type compounds are of special interest; while they share with 
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optovin the ability to induce light activated behaviors, they differ greatly in phenotype, 
wavelength response, vision dependence, and target.  
 
However, one potential constraint should be noted while interpreting this data. Due to the limited 
availability of mutant fish, genetic experiments were limited to 5 fish/well instead of the usual 
eight, which has previously been demonstrated to produce the strongest results when using our 
automated behavioral phenotyping system42. Consequently, more subtle phenotypes and any 
differences in WT versus mutant fish may have been suppressed, especially from compounds 
tested at lower doses. Additionally, only a selected subset of compounds from each phenotypic 
group could be tested in the ATOH7 KO fish. Because of this, while certain trends can be 
observed, it is difficult to draw conclusions about the role of ATOH7 in each hit compound 
group. Further studies utilizing 8 fish/well and additional replicates will be important for a 
comprehensive understanding of the targets of these hit compounds, and will continue once 
activity restrictions resulting from the COVID-19 pandemic have been lifted.  
 
Future directions 
While this study has revealed that a wide diversity of structures, photochemical properties, 
behaviors, and toxicities exist among light-dependent TRPA1 agonists, further research is 
needed to better understand both the mechanisms and the research or therapeutic potential of 
these compounds. Further structural analyses would help to elucidate the chemical moieties 
and energy changes responsible for light activation, allowing for the development of purpose-
build analogues. Likewise, a better understanding of receptor-compound kinetics and the 
mechanisms of the hit compounds would help to answer questions about where and how the 
compound is binding, whether light activation occurs at the receptor-compound complex or on 
the compound alone, and whether any intermediates or downstream signaling pathways of 
TRPA1 play a role in the induced behaviors. To this end, patch clamp experiments could help to 
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reveal patterns of channel opening and the location of binding, while mutations in potential 
TRPA1 binding sites could confirm those locations43. The presence of intermediates such as 
reactive oxygen species (ROS) could be detected by co-treating with DABCO, a ROS quencher, 
or by using a singlet oxygen indicator dye such as singlet oxygen green41, while bleaching or 
“pre-activation” of compounds would help to determine if exposure of only the compound to light 
is sufficient to induce the observed phenotypes. To ascertain the activity of these hit compounds 
on an organism-wide level, experiments on headless fish (as described in Kokel et al. 201341) 
could identify whether the compounds act in the brain or in the periphery, and if in the brain, 
pERK imaging could identify the specific location, while mass spectrometry analysis could 
reveal the neurotransmitters affected. Finally, it is crucial to determine whether these results 
carry over into other species. Mouse studies would reveal the effect of these compounds in a 
mammalian model, and comparisons to the effects of known TRPA1 agonists such as AITC 
could reveal key differences in their action. Furthermore, experiments on human TRPA1 
transfected cells would confirm the compounds’ ability to induce an effect in humans, and 
thereby open the door for potential medical research or therapeutic use. 
 
METHODS 
 
Fish maintenance, breeding, and compound treatments 
Eggs (up to 10,000 per day) were collected from group matings of wild-type “Singapore” 
zebrafish, and raised until 7dpf on a 14/10-hour light/dark cycle at 28oC in egg water (60 µg/ml 
“Instant Ocean” Sea Salts in distilled water, then buffered and brought to a pH of 7.0-7.4 using 
sodium bicarbonate44). Following sorting for healthy zebrafish and temporary anesthetization 
using egg water chilled to 4oC, eight larvae (as described in McCarroll et al. 201928) and 300µL 
of egg water per well were distributed into square 96-well plates (GE Healthcare Life Sciences) 
using a p1000 pipette. Plates were allowed to return to room temperature over 1 hour, after 
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which compounds diluted in DMSO were applied directly to the egg water. Larvae were 
incubated following treatment for an additional hour before behavioral analysis. All zebrafish 
procedures were approved by the UCSF’s Institutional Animal Care Use Committee (IACUC) in 
accordance with the Guide to Care and Use of Laboratory Animals (National Institutes of Health 
1996) and conducted according to established protocols that complied with ethical regulations 
for animal testing and research. 
 
Compound preparation and chemical libraries 
Chemical libraries were selected and purchased from the Chembridge DIVERSet Screening 
Libraries. All chemical library compounds were stored at -80C and dissolved in DMSO, then 
further diluted in DMSO and screened at a final concentration of 10µM in <1% DMSO. All 
controls were treated with an equal volume of DMSO. Hit compounds were obtained from 
commercial sources (Hit2Lead, TimTec, Molport, Vitas, Mcule, ChemDiv). Optovin was obtained 
from Tocris (4901), DMSO from Sigma Aldrich, AITC from Sigma Aldrich (36682-1G), and 
cinnamaldehyde from Sigma Aldrich. Following receipt, compounds were initially diluted to 
30mM stock solutions in DMSO and stored at -20oC. Immediately prior to treatment, compounds 
were thawed at room temperature and further diluted with DMSO as required. 
 
Automated behavioral phenotyping assays 
Phenotypes were induced and recorded using a custom-built instrument that includes a camera, 
lighting, and various light, audio, and physical stimuli, as described in Myers-Turnbull et al. 
202042 and McCarroll et al. 201928. Briefly, plates were placed in the instrument on a custom 
build acrylic stage and illuminated with a 760nm infrared light, and an AVT Pike digital camera 
(Allied Vision) fitted with an infrared-passing/visible light-blocking filter (LEE Filters LE8744 
polyester #87) and mounted to a telecentric lens captured images at 25fps. Light stimuli were 
delivered using high-intensity LEDs and included red at 623nm (1537-1041-ND, DigiKey), green 
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at 525nm (1537-1039-ND, DigiKey), blue at 460nm (1537-1037-ND, DigiKey), and violet at 
400nm (LZ4-40UB00-00U7, Mouser). Acoustic stimuli were delivered using a computer to 
playback audio stimuli as MP3s using an APA150 150W powered amplifier (Dayton Audio) 
played through surface transducers adhered to the acrylic stage. Physical tapping stimuli were 
delivered using push-style solenoids (12V) to tap the stage. Instrument control, including data 
acquisition and stimulus activation, was conducted using custom MATLAB and Python scripts. 
Processing of video data to the zebrafish motion index (MI) was calculated as follows: 
MI = sum(abs(framen – framen−1)). 
 
Optovin and TRPA1b agonist activity analysis 
Optovin phases were identified from data collected during a single, 10 minute long purple 
stimulus. Phases were defined as follows: Pre-stimulus (“pre”) begins at the start of the battery 
and ends at stimulus start. The average of this phase is also the optovin baseline. Phase 1 
(“P1”) begins at stimulus start and ends following the occurrence of the lowest MI within the first 
30s of response. Phase 2 (“P2”) begins following P1 and ends following the occurrence of the 
first MI value that is less than or equal to the optovin baseline. Phase 3 (“P3”) begins following 
P2 and continues through the end of the stimulus. Post-stimulus (“post”) begins following the 
end of the stimulus and continues through the end of the battery. Average MI values are 
averages throughout each phase for each individual well, which are then averaged across all 
wells. Overall optovin activity in response to different stimulus wavelengths is shown as AUC, 
calculated as the sum of all MI values during the sixth one minute stimulus for each well, then 
averaged over all replicate wells. Optovin activity in comparison to known TRPA1 agonists is 
displayed as fold change vs. DMSO for each phase. Phases for all conditions are defined by 
optovin activity (as above), and values calculated by averaging MI over each phase for each 
well, then averaging data across all wells. Fold change was calculated by dividing each of these 
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values by the average DMSO value. Significance was calculated vs. optovin using Welch’s t-
test. 
 
Compound screen hit identification and hit retest analysis 
To identify first-level hits from screened library compounds, “regions of interest” (ROIs) 
containing violet wavelength stimulus were identified for each assay within the full battery. 
Average MI values from each ROI were then obtained for all compounds. Fold change vs. 
DMSO was then calculated by dividing values from each ROI for each compound by the 
averaged data from the equivalent DMSO control ROI from the same plate. A fold change value 
for each DMSO well was calculated in the same way, with ROIs from each DMSO on a plate 
divided by averaged data from the equivalent ROI for all other DMSO controls from the same 
plate. The maximum fold change value from each compound and DMSO was then selected and 
plotted as a histogram. Compounds that had a maximum fold change greater than +3σ from the 
mean were selected for further analysis. Following initial identification, hits were further filtered 
by several levels of analyses. Manual analysis of compound screen MI traces and video 
removed any anomalous traces, after which retesting at 10µM against the screening battery with 
three replicates identified compounds with reproducible phenotypes. Compounds that 
reproduced were then selected for dose-response testing at 8 doses between 0.78125µM and 
100µM (x6 replicates) against the screening battery. ROIs were again selected and average MI 
values calculated. Significance for ROIs from each compound was calculated vs. same-plate 
DMSO wells using Welch’s t-test. A dummy DMSO significance value was obtained by 
randomly splitting DMSO replicates from each plate into the “test” and “control” groups. The 
significance threshold was determined after applying the Bonferroni correction (0.05/3014 tests). 
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Photochemical analysis 
Hit compounds and optovin were diluted to 100µM in egg water. An equal volume of DMSO in 
egg water and plain egg water were used as controls. To measure excitation/emission 
wavelengths, a 3D Fluorescence Scan was performed on a Tecan Spark. Compounds were 
plated onto a Grenier 384 well plate (Sigma, M6811). Emissions were measured every 20nm 
from 375-735nm, and excitations were measured every 20nm from 350-690nm. To measure 
absorbance, an Absorbance Spectrum experiment was performed on a SpectraMax M5 
Microplate Reader (Molecular Devices). Compounds were plated onto a 384 well UV Star plate 
(Grenier Bio-One, 781801). Absorbance wavelengths were measured every 20nm from 250-
750nm at 25C. For the multiple irradiation experiments, compounds were plated, then placed 
into the custom phenotyping instrument with the violet light stimulus activated. Immediately after 
light exposure, absorbance was measured as described above. Compounds were exposed to 
the violet light for varying lengths of time between 5 and 1200s and were freshly plated for each 
exposure.  
 
Phototoxicity assay 
Fish were incubated with hit compounds for 1 hour prior to stimulus exposure. After incubation, 
fish were placed into the behavioral phenotyping instrument and their activity tracked for 12 
hours. During the first six, larvae were exposed to a light stimulus at one wavelength (blue 
(460nm), violet (395nm), red (660nm), green (523nm), or no stimulus), after which activity was 
tracked for an additional six hours. Time of death was determined by identifying the 5 minute 
window in which the standard deviation of activity (as measured by MI) was equal to or less 
than the overall standard deviation of activity in the 300μM eugenol-treated positive controls. 
Additionally, the standard deviation of the remainder of the MI trace (beginning after the 5 
minute window) could not exceed the eugenol standard deviation; if it did, the next 5 minute 
window was selected and tested as above. Wells that did not meet these criteria within the 12 
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hour period were considered to have survived. Average length of survival was calculated by 
averaging time of death across all wells treated with the same compound and exposed to the 
same stimulus. Significance was calculated using Welch’s t-test. For the violet, blue, red, and 
green conditions, the same compound with no stimulus exposure was used as the control. For 
the no stimulus condition, DMSO with no stimulus exposure was used as the control. A p-value 
of 0 indicates no difference from the control.  
 
Structural and phenotypic clustering 
Structural clustering was performed with custom Python scripts using the SciPy hierarchical 
clustering (fcluster, linkage) and distance (pdist, parameters: metric = ‘jaccard’) functions. 
Phenotypic tSNE analysis was performed on full MI traces with custom Python scripts using the 
scikit-learn tSNE function (parameters: perplexity=10, learning_rate=500, n_iter=3000, 
n_iter_without_progress=500). Pairwise comparisons of selected features were performed by 
first selecting features of interest and calculating the relevant values for each compound, 
including phases “pre”, P1, P2, and “post” (individually) vs. DMSO fold change, P1 and P2 
(individually) vs. baseline fold change, and average MIs for each individual phase. Each of 
these values was then plotted in a pairwise fashion and analyzed manually to identify the 
features that generated the greatest separation. Heatmaps were plotted by averaging MI values 
by second and using the Seaborn clustermap function. Final phenotypic classifications were 
determined manually. Following classification, phenotypic groups were retroactively labelled on 
the tSNE analysis and pairwise feature comparison to verify that manual classification was in 
agreement with quantitative clustering.  
 
TRPA1b KO and ATOH7 KO zebrafish line development 
The TRPA1b KO zebrafish line was generated using CRISPR to target a sequence (5' 
CTGCACTATGCTTCAGCTGG 3') in exon 3 of the trpa1b gene. Injections were performed as 
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described in Burger et al. 201645. The F0 generation was allowed to mature into adults, then 
crossed with WT TUAB zebrafish. The resulting F1 generation was checked for the presence of 
a mutation using PCR and restriction digest with PvuII. DNA from fish with a mutation was then 
sequenced to confirm that the mutation introduced a stop codon, and F1s that had the same 
mutation were incrossed. From the F2 generation, TRPA1b -/- fish were selected and crossed, 
resulting in an F3 generation consisting entirely of TRPA1b -/- fish. To obtain larvae for 
experiments, F2 or F3 TRPA1b -/- fish were placed in breeding tanks with males and females 
separated the night before crossing. The next morning, the divider was pulled and any resulting 
embryos were collected. Larvae were used for behavioral experiments at 7dpf. ATOH7 (Lakritz) 
zebrafish larvae were generously provided by the Schoppik lab at NYU. Once the larvae were 
mature, fish were genotyped using PCR and restriction digest with StuI, and ATOH7 +/- fish 
were incrossed. ATOH7-/- larvae, which are visibly darker than ATOH+/+ or +/- fish, were then 
selected and raised. Because ATOH7-/- zebrafish are blind, it is necessary for them to be raised 
separately from homozygous or heterozygous fish to prevent outcompetition for food, and it is 
critical that for the first two weeks, the fish are provided with a high density of live food. To this 
end, starting at 5dpf, ATOH7-/- fish were raised in a separate tank and provided with at least 
150mL live paramecia per day. From 14dpf to 20dpf, fish were fed with both live paramecia and 
dry food (Gemma 75). Beginning at 21dpf, fish were fed with dry food only. Larvae for 
experiments were obtained by crossing ATOH7-/- fish and following the breeding and collection 
protocol above.  
 
TRPA1b KO and ATOH7 KO zebrafish analysis 
To assess whether the novel hit compounds depend on the TRPA1b receptor to induce a 
phenotype, WT and TRPA1b KO zebrafish larvae were treated with the same compounds and 
the activity response compared. Due to limitations on the availability of KO fish, only five fish 
were used per well. Following selection of regions of interest (P1, full 1 minute stimulus, first 
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three 1 minute stimuli), the mean MI for each of these ROIs was calculated. Fold change vs. 
control was then determined by dividing by the equivalent MI values from background-matched 
DMSO controls. Significance between WT and TRPA1b KO responses was determined using 
Welch’s t-test. To assess whether vision is required for the hit compounds to induce a 
phenotype, WT and ATOH7 KO fish were compared in a similar fashion. However, because the 
controls were too variable, mean MI values were used for comparison and to determine 
significance rather than fold change. 
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